Life science analytics forecast points to $64.51 billion market by 2030, with AI adoption driving growth

New research on the life science analytics industry estimates strong growth through the end of the decade, projecting the market will reach $64.51 billion by 2030. The report, publicized on a business news feed on Oct. 14, 2026, frames the expansion around rising adoption of analytics tools and AI capabilities used by pharmaceutical, biotech, and healthcare stakeholders as they pursue precision medicine approaches.

According to the report announcement, the sector is expected to grow at a 15.6% compound annual growth rate. The company or organization behind the study describes the market as driven by “AI adoption” and broader precision medicine initiatives, positioning analytics as a key layer for turning clinical and operational data into decisions for research, development, and care delivery.

The announcement also names major technology and life sciences data players as examples of vendors discussed within the market landscape. Companies referenced include Oracle, SAS, IBM, IQVIA, and Microsoft, with the report’s framing suggesting these firms are working to accelerate AI usage across life science analytics use cases.

For Microsoft, the mention appears to function as part of the competitive picture rather than a specific, newly disclosed product launch or customer win. The announcement does not provide details about a contract, partnership, or new Microsoft offering. Instead, it places Microsoft within a broader category of enterprise vendors that provide data, analytics, and AI-related capabilities that life science organizations can deploy.

More broadly, life science analytics typically refers to systems that combine and analyze data from multiple sources such as clinical trials, lab and manufacturing operations, real-world evidence, and population health datasets. In precision medicine, those analytics are often used to support tasks like patient stratification, treatment selection, and the assessment of outcomes in more individualized ways than traditional “one size fits all” approaches.

Sector observers note that AI integration in healthcare analytics is not only about improving predictive modeling, but also about managing the practical workflow around regulated data. That includes data preparation, governance, and traceability, especially when analytics outputs are used to support research decisions or inform clinical and operational planning. The report announcement points to AI adoption as a central tailwind, though it does not specify which technical approaches are most responsible for the forecast.

The forecast’s key figure and headline drivers are clear, but the announcement does not lay out methodological details such as how the market was sized, what specific product categories were included, or how different regions or customer segments were weighted. It also does not specify whether the $64.51 billion figure includes software only, services, or both, nor does it provide a breakdown of submarkets, leading competitors by segment, or the specific conditions that could accelerate or slow adoption.

As the industry looks ahead, investors and business leaders will likely watch for evidence that analytics and AI deployments in life sciences are translating into sustained budgets across large pharma and biotech, and for signs that regulatory and data governance practices keep pace with AI model adoption. Additional public disclosures, such as vendor customer announcements or procurement trends, would help confirm how quickly the forecast’s growth expectations are being realized. The report announcement itself, however, stops short of providing those specifics.